Lundbeck's Bexicaserin Insights Rock Epilepsy Congress
Breaking Down Bexicaserin's Dual Action Seems like Lundbeck's playing the long game with bexicaserin, and boy, are they shaking things up at the European Epilepsy Congress. This isn't your usual sit-back-and-watch situation. They're putting bexicaserin's dual mode of action under a magnifying glass, aiming to hit both sides of the brain's seesaw by increasing inhibitory...
Continue Reading